Compare EBF & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBF | DSGN |
|---|---|---|
| Founded | 1909 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.2M | 504.7M |
| IPO Year | N/A | 2021 |
| Metric | EBF | DSGN |
|---|---|---|
| Price | $18.28 | $9.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 234.5K | ★ 442.6K |
| Earning Date | 12-22-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.53% | N/A |
| EPS Growth | ★ 4.41 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $388,740,000.00 | N/A |
| Revenue This Year | $0.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.30 | $2.60 |
| 52 Week High | $22.01 | $10.31 |
| Indicator | EBF | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.17 | 62.56 |
| Support Level | $17.89 | $8.43 |
| Resistance Level | $18.47 | $9.68 |
| Average True Range (ATR) | 0.42 | 0.71 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 52.31 | 82.35 |
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.